Citations

Clear

9383 citation(s) found for "Thomas, PS".

Uric Acid Crystal Deposition Triggers Tubule Dilation in Normal Kidneys and Cystogenesis in Polycystic Kidney Disease (PKD)
Strubl, Sebastian , Holznecht, Nickolas J., Aceves, Brina A., Schimmel, Margaret, Asplund, David A., Kroes, Bradley C. , Mueller, Roman-Ulrich, Torres, Jacob A. , Arjune, Sita , Mueller, Roman-Ulrich, Harris, Peter C. , Weimbs, Thomas

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 33 | Issue: 11S | Pages: 392-392

10.1681/asn.20223311s1392c Get It

Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer
Lee, W. Robert , Dignam, James J., Amin, Mahul B. , Bruner, Deborah Watkins , Low, Daniel A. , Shah, Amit B. , D’Souza, David , Michalski, Jeff M. , Dayes, Ian S. , Seaward, Samantha A. , Hall, William A. , Nguyen, Paul L. , Pisansky, Thomas M. , Faria, Sergio , Chen, Yuhchyau , Rodgers, Joseph P., Bruner, Deborah , Swanson, Gregory P , Michalski, Jeff M , Dayes, Ian S , Seaward, Samantha A , Hall, William A , Sandler, Howard M , Swanson, Gregory P. , Sandler, Howard M.

Mayo Clinic

Journal of Clinical Oncology | May 17, 2024 | Volume: 42 | Issue: 20 | Pages: 2377-2381

10.1200/jco.23.02445 | PMID 38759121 Get It

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. NRG Oncology RTOG 0415 is a randomized phase III noninferiority (NI) clinical trial comparing conventional fractionation (73.8 Gy in 41 fractions) radiotherapy (C-RT) with hypofractionation (H-RT; 70 Gy in 28) in patients with low-risk prostate cancer. The study included 1,092 protocol-eligible patients initially reported in 2016 with a median follow-up of 5.8 years. Updated results with median follow-up of 12.8 years are now presented. The estimated 12-year disease-free survival (DFS) is 56.1% (95% CI, 51.5 to 60.5) for C-RT and 61.8% (95% CI, 57.2 to 66.0) for H-RT. The DFS hazard ratio (H-RT/C-RT) is 0.85 (95% CI, 0.71 to 1.03), confirming NI ( P < .001). Twelve-year cumulative incidence of biochemical failure (BF) was 17.0% (95% CI, 13.8 to 20.5) for C-RT and 9.9% (95% CI, 7.5 to 12.6) for H-RT. The HR (H-RT/C-RT) comparing biochemical recurrence between the two arms was 0.55 (95% CI, 0.39 to 0.78). Late grade ≥3 GI adverse event (AE) incidence is 3.2% (C-RT) versus 4.4% (H-RT), with relative risk (RR) for H-RT versus C-RT 1.39 (95% CI, 0.75 to 2.55). Late grade ≥3 genitourinary (GU) AE incidence is 3.4% (C-RT) versus 4.2% (H-RT), RR 1.26 (95% CI, 0.69 to 2.30). Long-term DFS is noninferior with H-RT compared with C-RT. BF is less with H-RT. No significant differences in late grade ≥3 GI/GU AEs were observed between assignments (ClinicalTrials.gov identifier: NCT00331773 ).
Ventilatory Assistance Before Umbilical Cord Clamping in Extremely Preterm Infants
Petroni, Gina R. , Varhegyi, Nikole, Strand, Marya L. , Josephsen, Justin , Niermeyer, Susan , Barry, James S. , Fang, Jennifer L. , Thomas, Sumesh , Kane, Andrea F., Byrne, Bobbi J., Underwood, Mark A. , Poulain, Francis R., Law, Brenda Hiu Yan , Gorman, Terri, Leone, Tina A. , Bulas, Dorothy , Epelman, Mónica , Chisholm, Christian A., Kattwinkel, John, Duda, Gina M, Thielen, Monika, Liedl, Lavonne M., Amsbaugh, Amy, Lamprecht, Amy, Berlinski, Carolyn S, Johnson, Jacque-Lynne F, Irvine, Leigh , Ciorogariu-Ivan, Anna-Maria, Pesavento, Rosa R, Fray, Caroline , Athaide, Melba, Fairchild, Karen D. , Warren, Jamie B. , Rincon, Monica P. , Travers, Colm P. , Carlo, Waldemar A. , Kline‐Fath, Beth M. , Hawkins, Melissa, Ciorogariu‐Ivan, Anna‐Maria

Mayo Clinic

JAMA Network Open | May 17, 2024 | Volume: 7 | Issue: 5 | Pages: e2411140

10.1001/jamanetworkopen.2024.11140 | PMID 38758557 Get It

ImportanceProviding assisted ventilation during delayed umbilical cord clamping may improve outcomes for extremely preterm infants.ObjectiveTo determine whether assisted ventilation in extremely preterm infants (23 0/7 to 28 6/7 weeks’ gestational age [GA]) followed by cord clamping reduces intraventricular hemorrhage (IVH) or early death.Design, Setting, and ParticipantsThis phase 3, 1:1, parallel-stratified randomized clinical trial conducted at 12 perinatal centers across the US and Canada from September 2, 2016, through February 21, 2023, assessed IVH and early death outcomes of extremely preterm infants randomized to receive 120 seconds of assisted ventilation followed by cord clamping vs delayed cord clamping for 30 to 60 seconds with ventilatory assistance afterward. Two analysis cohorts, not breathing well and breathing well, were specified a priori based on assessment of breathing 30 seconds after birth.InterventionAfter birth, all infants received stimulation and suctioning if needed. From 30 to 120 seconds, infants randomized to the intervention received continuous positive airway pressure if breathing well or positive-pressure ventilation if not, with cord clamping at 120 seconds. Control infants received 30 to 60 seconds of delayed cord clamping followed by standard resuscitation.Main Outcomes and MeasuresThe primary outcome was any grade IVH on head ultrasonography or death before day 7. Interpretation by site radiologists was confirmed by independent radiologists, all masked to study group. To estimate the association between study group and outcome, data were analyzed using the stratified Cochran-Mantel-Haenszel test for relative risk (RR), with associations summarized by point estimates and 95% CIs.ResultsOf 1110 women who consented to participate, 548 were randomized and delivered infants at GA less than 29 weeks. A total of 570 eligible infants were enrolled (median [IQR] GA, 26.6 [24.9-27.7] weeks; 297 male [52.1%]). Intraventricular hemorrhage or death occurred in 34.9% (97 of 278) of infants in the intervention group and 32.5% (95 of 292) in the control group (adjusted RR, 1.02; 95% CI, 0.81-1.27). In the prespecified not-breathing-well cohort (47.5% [271 of 570]; median [IQR] GA, 26.0 [24.7-27.4] weeks; 152 male [56.1%]), IVH or death occurred in 38.7% (58 of 150) of infants in the intervention group and 43.0% (52 of 121) in the control group (RR, 0.91; 95% CI, 0.68-1.21). There was no evidence of differences in death, severe brain injury, or major morbidities between the intervention and control groups in either breathing cohort.Conclusions and RelevanceThis study did not show that providing assisted ventilation before cord clamping in extremely preterm infants reduces IVH or early death. Additional study around the feasibility, safety, and efficacy of assisted ventilation before cord clamping may provide additional insight.Trial RegistrationClinicalTrials.gov Identifier: NCT02742454
Contour Neurovascular System for endovascular embolization of cerebral aneurysms: a multicenter cohort study of 10 European neurovascular centers
Griessenauer, Christoph J. , Ghozy, Sherief , Biondi, Alessandra , Hecker, Constantin , Wodarg, Fritz , Liebig, Thomas , Patankar, Tufail , Lamin, Saleh , Martínez‐Galdámez, Mario , Cognard, Christophe , Fiehler, Jens , Dmytriw, Adam A , Killer-Oberpfalzer, Monika , Martínez-Galdámez, Mario , Ghozy, Sherief , Cognard, Christophe , Hecker, Constantin , Griessenauer, Christoph J , Fiehler, Jens , Dorn, Franziska , Dmytriw, Adam A.

Mayo Clinic

Journal of NeuroInterventional Surgery | May 17, 2024 | Volume: 17 | Issue: 4 | Pages: 399-404

10.1136/jnis-2023-021378 | PMID 38760167 Get It

Background Intrasaccular devices have become increasingly popular in the treatment of cerebral aneurysms, particularly at the bifurcation. Here we evaluate the Contour Neurovascular System, an intrasaccular device for the endovascular treatment of cerebral aneurysms, in a multicenter cohort study, the largest to the best of our knowledge. Methods Consecutive patients with intracranial aneurysms treated with the Contour Neurovascular System between February 2017 and October 2022 at 10 European neurovascular centers were prospectively collected and retrospectively reviewed. Patient and aneurysm characteristics, procedural details, and angiographic and clinical outcomes were evaluated. Results During the study period, 279 aneurysms (median age of patients 60 years, IQR 52–68) were treated with Contour. In 83.2% of patients the device was placed electively, whereas the remaining patients were treated in the setting of acute subarachnoid hemorrhage. The most common locations were the middle cerebral artery (26.5%) followed by the anterior communicating region (26.2%). Median aneurysm dome and neck size were 5.2 mm (IQR 4.2–7) and 3.9 mm (IQR 3–5). Contour size 7 (39%) and 9 (25%) were most used. Thromboembolic and hemorrhagic complications occurred in 6.8% and 0.4% of aneurysms, respectively. Raymond-Roy 1 and 2 occlusions at last follow-up were achieved in 63.2% and 28.3%, respectively, resulting in adequate occlusion of 91.5% of aneurysms. Conclusion This is the largest multicenter study reporting the outcome on the Contour Neurovascular System. At 1 year, the self-evaluated data on safety and efficacy are comparable to data of existing intrasaccular devices. Contour is a promising technology in the treatment of cerebral aneurysms.
Interim Update of the MDR-101-MLK Phase 3 Trial: MERCURY Study
Marin, Ethan P., Stites, Erik, Busque, Stéphan , Mai, Martin L., Piper, James B., Shah, Asheh P., Akkina, Sanjeev , Group, Mercury Study, Kaufman, Dixon B. , Stegall, Mark D. , Gaber, A. Osama , Srinivas, Titte R. , Mai, Martin L., Cooper, Matthew , Crowley, Suzanne, Chavin, Kenneth D. , Group, Mercury Study

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 28-28

10.1681/asn.20203110s128a Get It

Outcomes of Mechanical Thrombectomy for Patients With Stroke Presenting With Low Alberta Stroke Program Early Computed Tomography Score in Early and Late Time Windows
Elawady, Sameh Samir , Uchida, Kazutaka , Maier, Ilko , Jabbour, Pascal , Kim, Joon‐Tae , Wolfe, Stacey Q , Rai, Ansaar , Starke, Robert M. , Psychogios, Marios‐Nikos , Grossberg, Jonathan A , Tanweer, Omar , Polifka, Adam , Crosa, Roberto , Park, Min S. , Brinjikji, Waleed , Moss, Mark, Dumont, Travis M., Williamson, Richard , Navía, Pedro , Kan, Peter , Chowdhry, Shakeel , Ezzeldin, Mohamad , Spiotta, Alejandro M , Crosa, Roberto , Wolfe, Stacey Quintero , Navia, Pedro , Cunningham, Conor M. , Matsukawa, Hidetoshi , Lin, Steven , Jabbour, Pascal , Samaniego, Edgar A , Arthur, Adam Stephen , Yoshimura, Shinichi , Cuellar, Hugo, Alawieh, Ali , Romano, Daniele G., Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Matouk, Charles , Levitt, Michael R. , Leacy, Reade De , Kasab, Sami Al

Mayo Clinic

Neurosurgery | May 17, 2024 | Volume: 95 | Issue: 4 | Pages: 877-885

10.1227/neu.0000000000002992 | PMID 39293795 Get It

BACKGROUND AND OBJECTIVES: This study aimed to compare outcomes of low Alberta Stroke Program Early Computed Tomography Score (ASPECTS) patients with stroke who underwent mechanical thrombectomy (MT) within 6 hours or 6 to 24 hours after stroke onset. METHODS: A retrospective cohort study was conducted using data from a large multicenter international registry from 2013 to 2023. Patients with low ASPECTS (2-5) who underwent MT for anterior circulation intracranial large vessel occlusion were included. A propensity matching analysis was conducted for patients presented in the early (<6 hours) vs late (6-24 hours) time window after symptom onset or last known normal. RESULTS: Among the 10 229 patients who underwent MT, 274 met the inclusion criteria. 122 (44.5%) patients were treated in the late window. Early window patients were older (median age, 74 years [IQR, 63-80] vs 66.5 years [IQR, 54-77]; P < .001), had lower proportion of female patients (40.1% vs 54.1%; P = .029), higher median admission National Institutes of Health Stroke Scale score (20 [IQR, 16-24] vs 19 [IQR, 14-22]; P = .004), and a higher prevalence of atrial fibrillation (46.1% vs 27.3; P = .002). Propensity matching yielded a well-matched cohort of 84 patients in each group. Comparing the matched cohorts showed there was no significant difference in acceptable outcomes at 90 days between the 2 groups (odds ratio = 0.90 [95% CI = 0.47-1.71]; P = .70). However, the rate of symptomatic ICH was significantly higher in the early window group compared with the late window group (odds ratio = 2.44 [95% CI = 1.06-6.02]; P = .04). CONCLUSION: Among patients with anterior circulation large vessel occlusion and low ASPECTS, MT seems to provide a similar benefit to functional outcome for patients presenting <6 hours or 6 to 24 hours after onset.
Parkinson's Disease Associated with G2019S LRRK2 Mutations without Lewy Body Pathology
Jackson, Lauren , Woodruff, Bryan K. , Tremblay, Cécilia , Shill, Holly A. , Beach, Thomas G. , Serrano, Geidy E., Adler, Charles H. , Jackson, Lauren M , Adler, C H , Serrano, Geidy E.

Mayo Clinic

Movement Disorders Clinical Practice | May 16, 2024 | Volume: 11 | Issue: 7 | Pages: 874-878

10.1002/mdc3.14068 | PMID 38757351 Get It

AbstractBackgroundThe G2019S leucine‐rich repeat kinase 2 (LRRK2) gene mutation is an important and commonly found genetic determinant of Parkinson's disease (PD). The neuropathological findings associated with this mutation have thus far been varied but are most often associated with Lewy body (LB) pathology.ObjectiveDescribe a case of clinical Parkinson's disease with levodopa responsiveness found to have LRRK2 mutations and the absence of Lewy bodies.MethodWe present an 89‐year‐old man with a 10‐year history of slowly progressive parkinsonism suspected to be secondary to Parkinson's disease.ResultsNeuropathological evaluation revealed nigral degeneration without Lewy bodies or Lewy neurites, but there were frequent tau‐immunopositive neurites and astrocytes in the putamen and substantia nigra, neocortical glial tau positive astrocytes associated with aging‐related tau astrogliopathy (ARTAG), as well as neurofibrillary tangles, beta amyloid plaques, and amyloid angiopathy typical of advanced Alzheimer's disease. G2019S LRRK2 homozygous mutations were found.ConclusionThis case illustrates that levodopa‐responsive clinical PD caused by G2019S LRRK2 mutations can occur without Lewy bodies.
Abstract 10: Trends in Blood Pressure Control With the Covid-19 Pandemic, 2017 to 2022: A Study of 17 US Health Systems in the PCORnet ® Blood Pressure Control Laboratory
Shaw, Kathryn M., Smith, Myra, O’Brien, Emily C. , Chamberlain, Alanna M. , Cooper‐DeHoff, Rhonda M. , Lin, Feng , Fontil, Valy , Carton, Thomas W. , Modrow, Madelaine Faulkner , Wozniak, Gregory , Rakotz, Michael , Smith, Steven M. , Pletcher, Mark J.

Mayo Clinic

Circulation | May 16, 2024 | Volume: 149 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.149.suppl_1.10 Get It

Background: The COVID-19 pandemic resulted in reduced in-person clinic visits and declines in blood pressure (BP) control among patients with hypertension. The purpose of this study was to report on pre- to post-pandemic trends in BP control and related BP metrics through 2022. Methods: We utilized data from 17 US health systems with electronic health record data standardized to the PCORnet ® Common Data Model. Multiple BP control metrics were calculated as a series of quarterly, 12-month rolling measurement periods from 2017 to 2022 (i.e., 1/1/2017-12/31/2017, 4/1/2017-3/31/2018, …, 1/1/2022-12/31/2022). BP control was defined as the percentage of patients with hypertension whose most recent BP measurement at an ambulatory visit was <140/<90 mmHg. Improvement in BP was defined as the percentage of patients with a reduction of 10 mmHg in systolic BP or achievement of systolic BP <140 mmHg during the last 3 months of the measurement period in patients with previously uncontrolled hypertension. Results: In 2022, 1,499,418 persons with hypertension were included (50% 65-85 years old; 47% men; 11% Hispanic, 3% non-Hispanic Asian, 20% non-Hispanic Black, 63% non-Hispanic White). BP control was relatively stable within health systems prior to the COVID-19 pandemic. Worsening of BP control was seen for most health systems in the second quarter of 2020 coinciding with onset of the COVID-19 pandemic (Figure, left panel). The weighted average BP control was 65.3% in 2019, dropped to 61.8% in 2020, and increased to 62.9% in 2021 and 62.6% in 2022. Similar patterns were observed for the improvement in BP metric (Figure, right panel): weighted average 31.4% in 2019, 25.7% in 2020, 29.1% in 2021 and 28.6% in 2022. Conclusion: BP control and improvement in BP decreased substantially during the COVID-19 pandemic. While both metrics improved after 2020, they were still below pre-pandemic levels through 2022. These findings underscore the importance of continued surveillance of BP control and other health impacts of the COVID-19 pandemic.
Bone Metastases
Cook, Gary , Thorpe, Matthew P, Thorpe, Matthew

Mayo Clinic

The Cancer Journal | May 16, 2024 | Volume: 30 | Issue: 3 | Pages: 202-209

10.1097/ppo.0000000000000717 | PMID 38753755 Get It

Abstract Bone metastases occur frequently in common malignancies such as breast and prostate cancer. They are responsible for considerable morbidity and skeletal-related events. Fortunately, there are now several systemic, focal, and targeted therapies that can improve quality and length of life, including radionuclide therapies. It is therefore important that bone metastases can be detected as early as possible and that treatment can be accurately and sensitively monitored. Several bone-specific and tumor-specific single-photon emission computed tomography and positron emission tomography molecular imaging agents are available, for detection and monitoring response to systemic therapeutics, as well as theranostic agents to confirm target expression and predict response to radionuclide therapies.
Non–Small Cell Lung Cancer, Version 4.2024
Riely, Gregory J. , Wood, Douglas E. , Ettinger, David S. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , DeCamp, Malcolm M., Desai, Aakash , Dilling, Thomas J. , Dowell, Jonathan E. , Durm, Gregory A. , Gettinger, Scott , Gubens, Matthew A. , Lackner, Rudy P., Maldonado, Fabien , Morgensztern, Daniel , Mullikin, Trey C. , Ng, Thomas, Owen, Dawn , Patel, Sandip Pravin , Riess, Jonathan W. , Shapiro, Theresa A. , Singh, Aditi P. , Stevenson, James, Tam, Alda L. , Yang, Stephen C. , Yau, Edwin , Gregory, Kristina M., Hang, Lisa, Desai, Aakash P , Bharat, Ankit , Chang, Joe Y. , Chirieac, Lucian R. , Grotz, Travis E. , Juloori, Aditya , Lanuti, Michael D. , Lin, Jules , Loo, Billy W. , Lovly, Christine Marie , Massarelli, Erminia , Owen, Dwight H , Patil, Tejas , Polanco, Patricio Marcelo , Tanvetyanon, Tawee , Yanagawa, Jane

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 16, 2024 | Volume: 22 | Issue: 4 | Pages: 249-274

10.6004/jnccn.2204.0023 | PMID 38754467 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance for relapse, and subsequent treatment. The panel has updated the list of recommended targeted therapies based on recent FDA approvals and clinical data. This selection from the NCCN Guidelines for NSCLC focuses on treatment recommendations for advanced or metastatic NSCLC with actionable molecular biomarkers.